190 related articles for article (PubMed ID: 31713130)
1. Dalbavancin Reduces Hospital Stay and Improves Productivity for Patients with Acute Bacterial Skin and Skin Structure Infections: The ENHANCE Trial.
McCarthy MW; Keyloun KR; Gillard P; Choi JJ; Pickell N; Copp R; Walsh TJ
Infect Dis Ther; 2020 Mar; 9(1):53-67. PubMed ID: 31713130
[TBL] [Abstract][Full Text] [Related]
2. Single Intravenous Dose Dalbavancin Pathway for the Treatment of Acute Bacterial Skin and Skin Structure Infections: Considerations for Emergency Department Implementation and Cost Savings.
LoVecchio F; McCarthy MW; Ye X; Henry AD; Doan QV; Lock JL; Riccobene T; Lyles RD; Talan DA
J Emerg Med; 2024 Mar; ():. PubMed ID: 38825531
[TBL] [Abstract][Full Text] [Related]
3. Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections for Self-Pay Patients.
Pizzuti AG; Murray EY; Wagner JL; Gaul DA; Bland CM; Jones BM
Infect Dis Ther; 2020 Dec; 9(4):1043-1053. PubMed ID: 33083894
[TBL] [Abstract][Full Text] [Related]
4. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
[TBL] [Abstract][Full Text] [Related]
5. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
Papavramidis T; Gentile I; Cattelan AM; Magnasco L; Viale P; Francisci D; Kofteridis DP; Tiseo G; Giamarellos-Bourboulis EJ; Lagi F; Pinna SM; D'Amico F; La Ferla L; Panagopoulos P; Gattuso G; Sipsas NV; Ruggieri A; Cattaneo A; Corio L; Comandini A; Mascagni P; Bassetti M
Int J Antimicrob Agents; 2023 Apr; 61(4):106746. PubMed ID: 36758778
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).
Bai F; Aldieri C; Cattelan A; Raumer F; Di Meco E; Moioli MC; Tordato F; Morelli P; Borghi F; Rizzi M; Van Hauwermeiren E; Castelli F; Migliorino G; Menzaghi B; Rizzardini G; Saracino A; Cascio A; Puoti M; d'Arminio Monforte A; Marchetti G
Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1271-1279. PubMed ID: 32797758
[TBL] [Abstract][Full Text] [Related]
7. Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials.
Gonzalez PL; Rappo U; Mas Casullo V; Akinapelli K; McGregor JS; Nelson J; Nowak M; Puttagunta S; Dunne MW
Infect Dis Ther; 2021 Mar; 10(1):471-481. PubMed ID: 33515414
[TBL] [Abstract][Full Text] [Related]
8. Outpatient care concept and potential inpatient cost savings associated with the administration of dalbavancin - A real-world data and retrospective cost analysis.
Baltin CT; Wulf C; Rongisch R; Lehmann C; Wingen-Heimann S; Eisenmenger N; Bonn J; Fabri M; von Stebut E; Cornely OA; Kron F
J Infect Public Health; 2023 Jun; 16(6):955-963. PubMed ID: 37099955
[TBL] [Abstract][Full Text] [Related]
9. Dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients: a case series.
Garbo V; Condemi A; Albano C; Polara VF; Parrino R; Macaluso A; Venuti L; Colomba C
Infez Med; 2024; 32(2):231-240. PubMed ID: 38827834
[TBL] [Abstract][Full Text] [Related]
10. Modeling operational quality metrics and costs of long-acting antibiotics for acute bacterial skin and skin structure infection treatment in the emergency department.
Keyloun KR; Lofgren E; Hebert S
J Med Econ; 2019 Jul; 22(7):652-661. PubMed ID: 30838908
[No Abstract] [Full Text] [Related]
11. Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries.
Marcellusi A; Bini C; Andreoni M; Sarmati L; Espin J; Horcajada JP; Czypionka T; Andretta D; Sciattella P; Favato G; Mennini FS
Clin Drug Investig; 2020 Apr; 40(4):305-318. PubMed ID: 32034687
[TBL] [Abstract][Full Text] [Related]
12. Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment - a health economic analysis using German DRG data.
Wilke M; Worf K; Preisendörfer B; Heinlein W; Kast T; Bodmann KF
GMS Infect Dis; 2019; 7():Doc03. PubMed ID: 31728264
[TBL] [Abstract][Full Text] [Related]
13. Cost-Consequence Analysis of Single-Dose Dalbavancin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections in a Multisite Healthcare System.
Gonzalez J; Andrade DC; Niu J
Clin Infect Dis; 2021 Oct; 73(7):e1436-e1442. PubMed ID: 33211794
[TBL] [Abstract][Full Text] [Related]
14. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting.
Ektare V; Khachatryan A; Xue M; Dunne M; Johnson K; Stephens J
J Med Econ; 2015; 18(12):1092-101. PubMed ID: 26368787
[TBL] [Abstract][Full Text] [Related]
15. The role of long-acting antibiotics in the clinical practice: a narrative review.
Micheli G; Chiuchiarelli M; Taccari F; Fantoni M
Infez Med; 2023; 31(4):449-465. PubMed ID: 38075413
[TBL] [Abstract][Full Text] [Related]
16. Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections.
LaPensee K; Lodise T
Am Health Drug Benefits; 2018 Dec; 11(9):449-459. PubMed ID: 30746017
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Leuthner KD; Buechler KA; Kogan D; Saguros A; Lee HS
Ther Clin Risk Manag; 2016; 12():931-40. PubMed ID: 27354809
[TBL] [Abstract][Full Text] [Related]
18. The Safety and Efficacy of Dalbavancin and Active Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections.
Giorgobiani M; Burroughs MH; Antadze T; Carrothers TJ; Riccobene TA; Patel R; Lin T; Stefanova P
Pediatr Infect Dis J; 2023 Mar; 42(3):199-205. PubMed ID: 36476623
[TBL] [Abstract][Full Text] [Related]
19. Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections.
Rappo U; Gonzalez PL; Puttagunta S; Akinapelli K; Keyloun K; Gillard P; Liu Y; Dunne MW
J Glob Antimicrob Resist; 2019 Jun; 17():60-65. PubMed ID: 30797084
[TBL] [Abstract][Full Text] [Related]
20. Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals.
Bai F; Mazzitelli M; Silvola S; Raumer F; Restelli U; Croce D; Marchetti G; Cattelan AM
JAC Antimicrob Resist; 2023 Apr; 5(2):dlad044. PubMed ID: 37090914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
